Clinical Trial News and Research

RSS

Mindfit brain fitness program helps frail seniors walk faster

Computerized brain fitness programs are known to help seniors improve their memory and focus. Now, a study led by researchers at Albert Einstein College of Medicine of Yeshiva University has found preliminary evidence that such programs may help frail seniors walk faster, potentially preventing disability and improving quality of life. Results appear in the July 19 online edition of the Journal of Gerontology.

11 Aug 2010

Cardiovascular Systems fourth-quarter revenue increases 15% to $18.0 million

Cardiovascular Systems, Inc., a medical device company developing and commercializing innovative interventional treatment systems for vascular disease, today reported financial results for its fiscal fourth quarter and year ended June 30, 2010.

11 Aug 2010

Study suggests zinc supplementation may reduce pneumonia risk

A high proportion of nursing facility residents were found to have low serum (blood) zinc concentrations during an observational study funded by the Agricultural Research Service (ARS) and the National Institute of Aging. The scientists found that those with normal blood zinc concentrations were about 50 percent less likely to develop pneumonia than those with low concentrations.

11 Aug 2010

Inhibitex reports net loss of $5.6 million for second-quarter 2010

Inhibitex, Inc. today announced its financial results for the second quarter ended June 30, 2010.

10 Aug 2010

China Pharma second-quarter revenue increases 22% to $16.6 million

China Pharma Holdings, Inc., a leading fully-integrated specialty pharmaceuticals company in China, today announced financial results for the second quarter ended June 30, 2010.

10 Aug 2010

Amarin provides progress update on MARINE and ANCHOR trials for treating elevated triglyceride levels

Amarin Corporation plc, a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reports a financial update as of June 30, 2010. In addition, the Company provides a progress update of its MARINE and ANCHOR trials, the two on-going Phase 3 clinical trials of its lead product candidate AMR101 for treating elevated triglyceride levels.

10 Aug 2010

FDA approves human embryonic stem cells clinical trial for spinal cord injury treatment

Emerging Healthcare Solutions, Inc.: Last week, the US Food and Drug Administration gave their highly-anticipated approval for the first clinical trial using human embryonic stem cells (hESCs), which are the type of cells that can develop into all tissues of the body. Geron Corporation of Menlo Park, California, received the green light from the US FDA to use cells derived from hESCs to treat people with acute spinal cord injuries. Ten people will receive injections into the injury site of hESC-derived oligodendrocyte progenitor cells, which stimulate the growth of new and severed nerves and recoat damaged nerves with myelin. The hope is that the injections will help people recover function lost through injury, as seen in rodent studies in 2005.

10 Aug 2010

Transcept Pharmaceuticals second-quarter net loss decreases to $2.06 million

Transcept Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced financial results for the three and six months ended June 30, 2010.

10 Aug 2010

Array BioPharma fiscal 2010 revenue increases to $53.9 million

Array BioPharma Inc. today reported financial results for the fourth quarter and full year of fiscal 2010.

10 Aug 2010

Anika second-quarter product revenue increases 56% to $13.7 million

Anika Therapeutics, Inc., a leader in products for tissue protection, healing, and repair, based on hyaluronic acid technology, today reported financial results for the quarter ended June 30, 2010.

10 Aug 2010

Medivation net loss decreases from $8.9M in second-quarter 2010 to $7.2M in second-quarter 2011

Medivation, Inc. today provided a corporate update and reported its financial results for the second quarter ended June 30, 2010.

10 Aug 2010

Amarin completes enrollment in AMR101 Phase 3 MARINE clinical trial

Amarin Corporation plc, a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that its MARINE trial, a Phase 3 clinical trial of AMR101, has completed patient enrollment and randomization into the treatment phase of this trial. The Company indicated that top line results from this trial are expected early in 2011, towards the early part of the range of guidance provided previously.

10 Aug 2010

Repros Therapeutics second-quarter net loss decreases to $1.3 million

Repros Therapeutics Inc. today announced financial results for the second quarter ended June 30, 2010.

10 Aug 2010

GenMark second-quarter revenues increase 162% to $651,000

GenMark Diagnostics, Inc. today reported revenues of $651,000 for the quarter ending June 30, 2010, a 162% increase over second quarter 2009. Net loss for the second quarter was $5.1 million, or $0.60 per share, compared to a net loss of $4.3 million and $1.08 per share for the same period last year.

10 Aug 2010

Athersys second-quarter revenues increase to $1.9 million

Athersys, Inc. today announced its financial results for the quarter ended June 30, 2010.

10 Aug 2010

Curis announces preliminary results of GDC-0449 Phase II clinical trial in advanced ovarian cancer

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that it has received preliminary results from a Phase II clinical trial of GDC-0449 from Roche and Genentech, Curis' collaborator and a member of the Roche Group.

9 Aug 2010

Lentigen receives NIH SBIR grant for program on clinical vector for TCR immunotherapy targeted to melanoma

Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery technologies, announced today that it has received a National Institutes of Health (NIH) Small Business Innovation Research grant (SBIR) for a program on "Clinical Vector for TCR Immunotherapy Targeted to Melanoma". In this program, Lentigen will collaborate with Dr. Michael Nishimura, Professor of Surgery, at the Medical University of South Carolina (MUSC).

9 Aug 2010

Bellus Health reports net loss of $5.8M for second-quarter vs. net income of $14.27M for previous year

BELLUS Health Inc. reported today its financial results for the second quarter ended June 30, 2010. The Company also announced new initiatives to reduce its annual expenditures ("burn rate") by focusing its efforts on existing products and on supporting current and future strategic partnerships. All currency figures reported in this press release, including comparative figures, are in Canadian dollars, unless otherwise specified.

9 Aug 2010

Fibrocell Science submits clinical study report to FDA for azficel-T Phase II/III trial for acne scars

Fibrocell Science, Inc., a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today that it has submitted a clinical study report for its Phase II/III study of azficel-T for the treatment of moderate to severe acne scars to the U.S. Food & Drug Administration (FDA).

9 Aug 2010

CytRx reports net income for second-quarter 2010 compared to net loss for previous year

CytRx Corporation, a biopharmaceutical company specializing in oncology, today reported financial results for the three months and six months ended June 30, 2010 and provided a business update.

9 Aug 2010

Clinical Trial News and Research

Mindfit brain fitness program helps frail seniors walk faster

Cardiovascular Systems fourth-quarter revenue increases 15% to $18.0 million

Study suggests zinc supplementation may reduce pneumonia risk

Inhibitex reports net loss of $5.6 million for second-quarter 2010

China Pharma second-quarter revenue increases 22% to $16.6 million

Amarin provides progress update on MARINE and ANCHOR trials for treating elevated triglyceride levels

FDA approves human embryonic stem cells clinical trial for spinal cord injury treatment

Transcept Pharmaceuticals second-quarter net loss decreases to $2.06 million

Array BioPharma fiscal 2010 revenue increases to $53.9 million

Anika second-quarter product revenue increases 56% to $13.7 million

Medivation net loss decreases from $8.9M in second-quarter 2010 to $7.2M in second-quarter 2011

Amarin completes enrollment in AMR101 Phase 3 MARINE clinical trial

Repros Therapeutics second-quarter net loss decreases to $1.3 million

GenMark second-quarter revenues increase 162% to $651,000

Athersys second-quarter revenues increase to $1.9 million

Curis announces preliminary results of GDC-0449 Phase II clinical trial in advanced ovarian cancer

Lentigen receives NIH SBIR grant for program on clinical vector for TCR immunotherapy targeted to melanoma

Bellus Health reports net loss of $5.8M for second-quarter vs. net income of $14.27M for previous year

Fibrocell Science submits clinical study report to FDA for azficel-T Phase II/III trial for acne scars

CytRx reports net income for second-quarter 2010 compared to net loss for previous year

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer